Sharemaestro company-news research for Summit Therapeutics Inc. (SMMT), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
MEX
Mexico
Provisional evidence
Company news sentiment
Latest SMMT news and sentiment
Summit Therapeutics Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score53Neutral is 50
Early balanced news score
19/100 evidence confidence
78% direct company focus
14 current stories across 1 publishers
Current company news
Early balanced news score
14 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone77/100
→
Published 30-day score53/100
Latest source headline
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
finance.yahoo.com · 15 Sep 2026 10:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
14 current stories are mapped specifically to SMMT.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.101.
Confidence is 19/100, below the threshold for a firm score.
53/100
News scoreEarly balanced news score
19/100
Confidencethin evidence
78%/100
Company news14 company stories
92/100
Story agreement8/100 difference
News history
Daily score and story count over 30 days
19 Aug03 Sep17 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence2
0.101 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness36
recency-weighted evidenceAgreement92
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks12 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
20 Mar16 Jun11 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
11 Sep 202654MXN 290.119995+0.0%
04 Sep 202653MXN 290.119995+0.0%
28 Aug 202652MXN 290.119995+0.0%
21 Aug 202652MXN 290.119995+0.0%
14 Aug 202654MXN 290.119995+0.0%
07 Aug 202651MXN 290.119995+0.0%
31 Jul 202650MXN 290.119995+0.0%
24 Jul 202651MXN 290.119995+0.0%
Provisional evidence
News subjects
What is shaping the score
Earnings708 stories · 57%
Regulatory and legal503 stories · 21%
Market update502 stories · 14%
Analyst action631 stories · 7%
Source mix
Where the evidence comes from
finance.yahoo.com6312 stories · 86%
seekingalpha.com502 stories · 14%
Recurring subjects
Subjects appearing most often
Clinical Trials14Biotech12Lung Cancer6Fda Approval5Pharma3Oncology3Share Price2Nsclc2Intrinsic Value2Fourth Quarter2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral15 Sep 18:18
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 15 Sep 18:18 | 53 | +0 | 19/100 (-1) | 14 (+1) | Provisional |
| 13 Sep 23:59 | 53 | -3 | 20/100 (-5) | 13 (-3) | Provisional |
| 09 Sep 23:59 | 56 | -1 | 25/100 (-4) | 16 (+1) | Provisional |
| 07 Sep 23:59 | 57 | +4 | 29/100 (+2) | 15 (-1) | Provisional |
| 04 Sep 23:59 | 53 | +2 | 27/100 (+10) | 16 (-1) | Provisional |
| 03 Sep 23:59 | 51 | +0 | 17/100 (-1) | 17 (+2) | Provisional |
| 02 Sep 23:59 | 51 | -1 | 18/100 (-7) | 15 (-1) | Provisional |
| 27 Aug 23:59 | 52 | +0 | 25/100 (+1) | 16 (+2) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#1—Not directional
finance.yahoo.comDirect company coverageStored article
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Sustained OS Improvement Seen with Longer Follow-Up in Western Patients, Consistent across Geographic Regions; No New Safety Signals Observed Akeso-Sponsored HARMONi-2 OS Data Also Presented at WCLC 2026; Additional Data from Landmark China-Only Study Included Herein MIAMI, September 15, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Associatio
BiotechClinical TrialsFdaFourth QuarterLung CancerOncology
- Published
- 15 Sep 2026 10:00
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 1.7d old
- Duplicates
- 1 consolidated
#2—Not directional
seekingalpha.comDirect company coverageStored article
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
[Human Respiratory System] nopparit/iStock via Getty Images Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) on Sunday said ivonescimab significantly extended survival compared with Merck’s (MRK [https://seekingalpha.com/symbol/MRK]) Keytruda in a late-stage lung cancer trial conducted by its partner Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]) in China. Ivonescimab reduced the risk of death by 27% compared with Keytruda, also known as pembrolizumab, among previously untreated patients with advanced non-small cell lung cancer whose tumors expressed PD-L1. Median overa
Clinical TrialsFda ApprovalLung CancerPharma
- Published
- 13 Sep 2026 17:23
- News subject
- Regulatory and legal
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 3.4d old
- Duplicates
- 1 consolidated
#3—Not directional
finance.yahoo.comDirect company coverageStored article
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
Summit Therapeutics Inc. (NASDAQ:SMMT) said partner Akeso reported a statistically significant overall survival benefit for ivonescimab monotherapy over pembrolizumab in a prespecified interim analysis of Phase 3 HARMONi-2. The randomized, double-blind study enrolled 398 patients at 55 hospitals in China with previously untreated, PD-L1-positive advanced non-small cell lung cancer without sensitizing EGFR mutations or ALK translocations. Overall survival was a prespecified secondary endpoint. Earlier analysis showed median progression-free survival of 11.1 months with ivonescimab and 5.8 month
BiotechClinical TrialsEarnings
- Published
- 09 Sep 2026 01:32
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.0d old
- Duplicates
- 1 consolidated
#483Tone
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
Summit Therapeutics (NASDAQ:SMMT) has seen its share price surge by 28.19 percent week-on-week, primarily driven by the positive results of an ongoing clinical trial for its bispecific antibody, ivonescimab. In an updated report during the week, the listed biopharmaceutical firm said that its China-based partner, Akeso Inc., saw positive overall survival results from the randomized double-blind Phase 3 Harmoni-2 study evaluating ivonescimab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. It also reporte
BiotechCancer TreatmentClinical TrialsLung CancerShare Price
- Published
- 07 Sep 2026 05:53
- News subject
- Earnings
- Why this score
- Large positive market reaction, Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- High · 65/100
- 30-day weight
- 61.9% of the score · 9.8d old
- Duplicates
- 1 consolidated
#570Tone
finance.yahoo.comDirect company coverageStored article
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics SMMT stock climbed 17.3% on Thursday after its Chinese partner Akeso reported positive overall survival (OS) results for ivonescimab in a head-to-head phase III study against Merck's MRK blockbuster oncology drug, Keytruda (pembrolizumab), in certain patients with non-small cell lung cancer (NSCLC). The data provided fresh clinical validation for SMMT's lead oncology candidate and increased investor focus on the drug's potential in the United States and other licensed markets. Summit Therapeutics is developing ivonescimab in collaboration with Akeso. The company acquired an
BiotechClinical TrialsNsclcOncologyRegulation
- Published
- 04 Sep 2026 14:37
- News subject
- Earnings
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 50/100
- 30-day weight
- 30.7% of the score · 12.5d old
- Duplicates
- 1 consolidated
#6—Not directional
finance.yahoo.comDirect company coverageStored article
Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda. Continue Reading
BiotechClinical Trials
- Published
- 03 Sep 2026 17:29
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.4d old
- Duplicates
- 1 consolidated
#7—Not directional
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up. Continue Reading
BiotechClinical TrialsLung Cancer
- Published
- 03 Sep 2026 16:00
- News subject
- Market update
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 13.4d old
- Duplicates
- 1 consolidated
#8—Not directional
seekingalpha.comDirect company coverageStored article
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
* Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) said on Wednesday that partner Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]) reported positive overall survival results [https://seekingalpha.com/pr/20639170-ivonescimab-monotherapy-demonstrates-statistically-significant-overall-survival-benefit] for ivonescimab in the Phase III HARMONi-2 study. * Ivonescimab delivered a statistically significant improvement in overall survival benefit compared with pembrolizumab in patients with PD-L1-positive advanced or metastatic non-small cell lung cancer. * The drug had previousl
BiotechClinical TrialsLung Cancer
- Published
- 02 Sep 2026 22:09
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.2d old
- Duplicates
- 1 consolidated
#9—Not directional
finance.yahoo.comDirect company coverageStored article
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study
Shares of Summit Therapeutics SMMT rose 6.5% on Wednesday after the company's partner Akeso announced positive top-line results from the phase III HARMONi-GI1 study conducted in China in certain patients with biliary tract cancer (BTC). The study evaluated ivonescimab plus chemotherapy versus AstraZeneca AZN's blockbuster cancer drug Imfinzi (durvalumab) plus chemotherapy as a first-line treatment in patients with advanced BTC, a rare group of cancers affecting the bile ducts and gallbladder. Imfinzi, a PD-L1 monoclonal antibody, holds approvals across multiple cancer indications and is a key
BiotechClinical TrialsNsclcOncologyPhase Iii
- Published
- 27 Aug 2026 16:11
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.4d old
- Duplicates
- 1 consolidated
#1062Tone
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move?
Summit Therapeutics (SMMT) drew fresh attention after partner Akeso reported positive topline results from the Phase III HARMONi-GI1 trial of ivonescimab plus chemotherapy in advanced biliary tract cancer, highlighting another late stage data point around the drug. The HARMONi-GI1 update arrived alongside a series of recent ivonescimab milestones for Summit Therapeutics, and traders reacted quickly. The 1-day share price return was 6.51%, and the 7-day and 30-day share price returns were 8.54% and 8.58% respectively. However, the year-to-date share price return is down 18.78% and the 1-year to
BiotechClinical TrialsIntrinsic ValuePharmaRevenue GrowthShare Price
- Published
- 27 Aug 2026 11:06
- News subject
- Earnings
- Why this score
- Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 6.9% of the score · 20.6d old
- Duplicates
- 1 consolidated
#11—Not directional
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics (SMMT) Published Phase III HARMONi Results In The Lancet Oncology
Summit Therapeutics (NasdaqGM:SMMT) reported that Phase III HARMONi trial results for ivonescimab in EGFR-mutated NSCLC have been published in The Lancet Oncology. The pivotal data show significant clinical benefit for patients in the HARMONi study, according to the published results. The company highlighted that ivonescimab for EGFR-mutated NSCLC is currently under ongoing FDA regulatory review. The growing flow of late stage oncology and immunotherapy data makes it worth looking at companies applying similar approaches in AI driven drug discovery and clinical development through 74 profitabl
BiotechClinical TrialsFda Approval
- Published
- 27 Aug 2026 06:13
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.8d old
- Duplicates
- 1 consolidated
#12—Not directional
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics (SMMT) Is Up 8.5% After New Phase III Biliary Cancer Data For Ivonescimab
Summit Therapeutics reported that partner Akeso recently delivered positive topline Phase III HARMONi-GI1 data from China, where ivonescimab plus chemotherapy achieved statistically significant and clinically meaningful overall survival, progression-free survival, and response rate benefits over durvalumab plus chemotherapy in first-line advanced biliary tract cancer. This adds a second late-stage success for ivonescimab alongside the previously published HARMONi non-small cell lung cancer results and ongoing FDA review, reinforcing its potential as a bispecific PD-1/VEGF antibody across multi
BiotechClinical TrialsFda ApprovalPharma
- Published
- 27 Aug 2026 03:14
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.9d old
- Duplicates
- 1 consolidated
#13—Not directional
finance.yahoo.comDirect company coverageStored article
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
First Immunotherapy-Based Regimen to Show Statistically Significant and Clinically Meaningful PFS Benefit in a Global Phase III Study of EGFR-Mutated NSCLC after Third-Generation EGFR TKI Progression Updated OS Data to Be Presented at WCLC 2026 MIAMI, August 25, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful
Clinical TrialsFda ApprovalFourth QuarterImmunotherapyLung Cancer
- Published
- 25 Aug 2026 11:00
- News subject
- Earnings
- Why this score
- The headline reports news without a clear direction
- Company focus
- Company discussed · 86%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.6d old
- Duplicates
- 1 consolidated
#1463Tone
finance.yahoo.comDirect company coverageStored article
Summit Therapeutics Shares Rise After Bernstein SocGen Upgrade
Researcher looking through microscope ©Adobe Stock Images Summit Therapeutics (NASDAQ:SMMT) shares gained 1.1% in pre-market trading after Bernstein SocGen upgraded the biotechnology company to Market Perform from Underperform and raised its price target to $11.90 from $9.80. The broker said Summit's current valuation now provides a more appropriate reflection of the risk-adjusted intrinsic value of ivonescimab, the company's only late-stage drug candidate. However, Bernstein stopped short of adopting a bullish position, arguing that the treatment is unlikely to emerge as a broad replacement f
BiotechClinical TrialsFda ApprovalIntrinsic ValuePrice Target
- Published
- 25 Aug 2026 10:51
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 33/100
- 30-day weight
- 0.5% of the score · 22.6d old
- Duplicates
- 1 consolidated
Earlier company news
SMMT news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 37 older SMMT headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to SMMT, but the headline and available text are not mainly about Summit Therapeutics Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of SMMT sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.